The Discounted Cash Flow (DCF) valuation of Tibet Rhodiola Pharmaceutical Holding Co (600211.SS) is 47.61 CNY. With the latest stock price at 37.38 CNY, the upside of Tibet Rhodiola Pharmaceutical Holding Co based on DCF is 27.4%.
Based on the latest price of 37.38 CNY and our DCF valuation, Tibet Rhodiola Pharmaceutical Holding Co (600211.SS) is a buy. buying 600211.SS stocks now will result in a potential gain of 27.4%.
| Range | Selected | |
| WACC / Discount Rate | 7.7% - 10.3% | 9.0% |
| Long-term Growth Rate | 0.0% - 1.0% | 0.5% |
| Fair Price | 40.28 - 58.90 | 47.61 |
| Upside | 7.8% - 57.6% | 27.4% |